Relaxation effect of nitric oxide-donor on diabetic penile smooth muscle in vitro.
The primate model has been used for investigations on the physiology and pharmacology of erection. Recent in vitro investigations indicate that nitric oxide (NO)-donor act as the mediator of penile erection, but it is unclear whether NO-donor could enhance the relaxation effect of sildenafil on diabetic penile smooth muscle. To determine the relaxation effect of NO-donor on diabetic penile smooth muscle, we studied strips of corpus cavernosum tissue obtained from 15 diabetic cynomolgus monkey (Macaca fascicularis). Contraction was induced on isolated strips of corporal smooth muscle by norepinephrine; then relaxation was assessed with the administration of two agents: selective phosphodiesterase type 5 (PDE5) inhibitor (sildenafil citrate) and S-nitroso-N-acetylpenicillamine (SNAP), an NO-donor, and combination of both agents. Analysis of variance was used to compare the responses to the different agents under various treatments. It was concluded that NO-donor could not enhance the relaxation effect of sildenafil on corpus cavernosum of diabetic monkey.
Taher
A
A
Department of Urology, Faculty of Medicine, University of Indonesia, Jakarta.
Birowo
P
P
Kamil
S T
ST
Shahab
N
N
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000496:Alloxan; D000818:Animals; D006152:Cyclic GMP / Q000378:metabolism; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D007172:Erectile Dysfunction / Q000503:physiopathology*; D008252:Macaca fascicularis; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009569:Nitric Oxide / Q000502:physiology; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D010396:Penicillamine / Q000031:analogs & derivatives / Q000494:pharmacology*; D010413:Penis / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D010656:Phenylephrine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000494:pharmacology*
D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; C110881:S-nitro-N-acetylpenicillamine; D013450:Sulfones; D014665:Vasodilator Agents; D010656:Phenylephrine; D009569:Nitric Oxide; D000496:Alloxan; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D010396:Penicillamine; D006152:Cyclic GMP; D009638:Norepinephrine